Techne Corp., which makes products for the research and diagnostic markets, is buying U.K.-based Tocris for $124 million. Read more about this acquisition ...

Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2024.

Shares of Bio-Techne (NASDAQ:TECH) traded sharply lower in the early premarket trading on Wednesday after KeyBanc Capital Markets downgraded the stock, arguing that the life sciences firm is ...

Asset Management One Co. Ltd. lifted its stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) by 12.8% during the first ...

Bio-Techne Corp. failed to get shareholder approval on its executive compensation plan. While the vote is nonbinding, a no vote is rare. Only 35% of shareholders supported the plan during the so ...

View Bio-Techne Corporation TECH stock quote prices, financial information, real-time forecasts, and company news from CNN.

Bio-Techne on Wednesday beat Wall Street estimates for third-quarter profit, driven by growth in its unit that provides proteins, antibodies and other products for research and said it is ...

Bio-Techne CEO Charles Kummeth has started a two-year transition plan that will see him leave the top executive role, but maintain his position on the company’s board of directors, the ...

Bio-Techne Corp. topped $1 billion in full-year sales for the first time, its latest results showed Thursday, and the Minneapolis-based life science firm said it is beginning a two-year leadership ...